Kang‐Moon Lee

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 297 citations · Full text

Medicine, Clinical Sciences, Immunology +17

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Byong Duk Ye, Marina Pesegova, Olga Alexeeva et al. · The Lancet · 2019 · 209 citations · Full text

Medicine, Clinical Sciences, Immunology +11

Development and Validation of Novel Diagnostic Criteria for Intestinal Behçet's Disease in Korean Patients With Ileocolonic Ulcers

Jae Hee Cheon, Eun Soo Kim, Sung Jae Shin et al. · The American Journal of Gastroenterology · 2009 · 144 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +14

Risankizumab for Ulcerative Colitis

Edouard Louis, Stefan Schreiber, Remo Panaccione et al. · JAMA · 2024 · 110 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

Silvio Danese, Jean‐Frédéric Colombel, Milan Lukáš et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 93 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14